Kimberly-Clark's preliminary third-quarter organic sales drop and pending Kenvue mega-merger leave growth balanced against execution risk. At 16.8 times 2027 pro forma earnings, the 4.9% dividend yield fairly anchors valuation. We initiate coverage with a Hold rating and a $105.00 target.
Key points
- $104.10 per share prices Kimberly-Clark at 16.8 times 2027 estimated pro forma earnings, fully reflecting the business transformation.
- 4.9% dividend yield provides strong income support during a complex $34.7 billion acquisition of Kenvue.
- -1.3% organic sales decline in preliminary third-quarter results highlights lingering category deceleration and China retail headwinds.
The call
At $104.10, the stock price requires Kimberly-Clark to expand operating margins toward 18% while absorbing $18.3 billion in net debt and 281 million newly issued shares from the pending Kenvue merger. That expectation implies immediate synergy realization and steady demand across North American personal care and consumer health franchises.
Kimberly-Clark Diluted EPS and Dividends Paid Per Share- Diluted EPS ($)
- Dividends paid per share ($)
SEC filings (Form 10-K, 10-Q, 8-K pro formas) and analyst forecasts. Pro forma combined figures for 2026E and 2027E.
We believe the market is about right. While management delivers robust gross productivity savings of 6% of cost of goods sold, organic category growth has decelerated to 1.7%. Combined pro forma 2027 earnings of $6.18 per share fairly match the existing valuation, leaving shares balanced between cash return stability and integration execution.
Valuation
| Valuation Metric | Estimate |
|---|
| 2027 Pro Forma Combined Net Sales | $32,800M |
| 2027 Pro Forma Operating Profit | $5,700M |
| 2027 Attributable Net Income | $3,810M |
| Pro Forma Diluted Share Count | 616.3M |
| 2027 Pro Forma Diluted EPS | $6.18 |
| Target Forward P/E Multiple | 17.0x |
| 12-Month Price Target | $105.00 |
A 17.0 times forward multiple appropriately reflects Kimberly-Clark’s premier household brand portfolio and steady 4.9% dividend payout, discounted slightly against Procter & Gamble’s 22.3 times multiple due to elevated acquisition leverage. Total return of approximately 5.8% aligns with broader defensive staples, warranting a Hold rating.
Risks
- Merger integration hurdles: Combining Kenvue’s self-care business while divesting European personal care assets could disrupt operations and elevate restructuring costs, observable in rising transformation expenses.
- Persistent category slowdown: Lower-income consumer stress could accelerate trade-down into private labels, observable in declining North American market share and negative organic volume growth.
- Pulp and commodity inflation: Re-accelerating virgin fiber and petroleum input costs could compress gross margins, observable in rising benchmark wood pulp indices.
What would change my mind
A swift return to positive volume growth above 2% paired with accelerated debt paydown below 2.0 times net debt to EBITDA would turn us constructive on the stock.
